UBS O'Connor’s Pharvaris PHVS Stock Holding History

UBS O'Connor’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,000	Closed	-$505K	–	580
2023 Q4	$505K	Buy	+18,000	New	+$364K	0.02%	347

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Viking Global Investors

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

UBS O'Connor's PHVS Position: Q1 2024 in Review

UBS O'Connor sold out of Pharvaris (PHVS) in Q1 2024, closing a stake of 18,000 shares — an estimated $505K sold.

UBS O'Connor first reported a position in PHVS in Q4 2023 and held it in 1 quarter. The position peaked at $505K in Q4 2023. 35 funds tracked by Wall St. Rank hold PHVS as of Q1 2024.

UBS O'Connor reported no remaining Pharvaris position as of Q1 2024 after selling out during the quarter.
UBS O'Connor sold 18,000 Pharvaris shares in Q1 2024, an estimated $505K.
UBS O'Connor first reported a position in Pharvaris in Q4 2023 and held it in 1 quarter.
UBS O'Connor's Pharvaris position peaked at $505K in Q4 2023.
35 funds tracked by Wall St. Rank held Pharvaris as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.